Arcadia Biosciences Earnings Calls

Q1 2025 Beat
$1.90 (293.88%)
Release date May 08, 2025
EPS estimate -$0.98
EPS actual $1.90
EPS Surprise 293.88%
Revenue estimate 1.3M
Revenue actual 1.2M
Revenue Surprise -7.69%
Q4 2024 Missed
-$2.48 (-178.65%)
Release date Mar 20, 2025
EPS estimate -$0.89
EPS actual -$2.48
EPS Surprise -178.65%
Revenue estimate 1.15M
Revenue actual 1.216M
Revenue Surprise 5.74%
Q3 2024 Missed
-$0.87 (-12.99%)
Release date Nov 12, 2024
EPS estimate -$0.770
EPS actual -$0.87
EPS Surprise -12.99%
Revenue estimate 1.15M
Revenue actual 1.537M
Revenue Surprise 33.65%
Q2 2024 Missed
$0.780 (-49.68%)
Release date Aug 13, 2024
EPS estimate $1.55
EPS actual $0.780
EPS Surprise -49.68%
Revenue estimate 920K
Revenue actual 1.306M
Revenue Surprise 41.96%

Last 4 Quarters for Arcadia Biosciences

Below you can see how RKDA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q2 2024 Missed
Release date Aug 13, 2024
Fiscal end date Jun 30, 2024
Price on release $2.99
EPS estimate $1.55
EPS actual $0.780
EPS surprise -49.68%
Date Price
Aug 07, 2024 $2.62
Aug 08, 2024 $2.66
Aug 09, 2024 $2.66
Aug 12, 2024 $2.92
Aug 13, 2024 $2.99
Aug 14, 2024 $2.66
Aug 15, 2024 $2.77
Aug 16, 2024 $2.65
Aug 19, 2024 $2.71
4 days before 14.12%
4 days after -9.36%
On release day -11.04%
Change in period 3.44%
Q3 2024 Missed
Release date Nov 12, 2024
Fiscal end date Sep 30, 2024
Price on release $4.24
EPS estimate -$0.770
EPS actual -$0.87
EPS surprise -12.99%
Date Price
Nov 06, 2024 $4.16
Nov 07, 2024 $4.08
Nov 08, 2024 $4.05
Nov 11, 2024 $4.24
Nov 12, 2024 $4.24
Nov 13, 2024 $4.19
Nov 14, 2024 $3.86
Nov 15, 2024 $2.90
Nov 18, 2024 $2.84
4 days before 1.92%
4 days after -33.02%
On release day -1.18%
Change in period -31.73%
Q4 2024 Missed
Release date Mar 20, 2025
Fiscal end date Dec 31, 2024
Price on release $3.30
EPS estimate -$0.89
EPS actual -$2.48
EPS surprise -178.65%
Date Price
Mar 14, 2025 $3.23
Mar 17, 2025 $3.23
Mar 18, 2025 $3.30
Mar 19, 2025 $3.44
Mar 20, 2025 $3.30
Mar 21, 2025 $3.15
Mar 24, 2025 $3.14
Mar 25, 2025 $3.43
Mar 26, 2025 $3.31
4 days before 2.17%
4 days after 0.167%
On release day -4.55%
Change in period 2.34%
Q1 2025 Beat
Release date May 08, 2025
Fiscal end date Mar 31, 2025
Price on release $4.29
EPS estimate -$0.98
EPS actual $1.90
EPS surprise 293.88%
Date Price
May 02, 2025 $3.52
May 05, 2025 $3.87
May 06, 2025 $4.39
May 07, 2025 $4.30
May 08, 2025 $4.29
May 09, 2025 $3.88
May 12, 2025 $3.98
May 13, 2025 $4.12
May 14, 2025 $4.16
4 days before 21.88%
4 days after -3.03%
On release day -9.58%
Change in period 18.18%

Arcadia Biosciences Earnings Call Transcript Summary of Q1 2025

Summary of Key Points from Arcadia Biosciences Q1 2025 Earnings Call for Investors

Financial Performance:

  • Revenue Growth: Arcadia reported total revenues of approximately $1.2 million, a 22% increase YoY. Notably, Zola coconut water revenues surged by 90% compared to the previous year, primarily due to expanded distribution (70% increase).
  • Gross Margin: The gross margin for Q1 was reported at 43%, down from 52% in Q1 2024, attributed to the transition to a single product line (Zola).
  • Operating Expenses: Operating expenses decreased by 16% YoY, despite incurring nearly $500,000 in transaction-related fees during the quarter.

Product Performance and Strategy:

  • Zola Coconut Water: Continued strong performance, with positive consumer feedback and growth outpacing the overall coconut water category (Zola growth at 76% vs. 24% for the category).
  • New Product Development: Zola is set to launch a new product line (including flavors like lime and pineapple) in early 2026, with an existing appealing pipeline for innovation.
  • Inventory Management: Inventory levels are well-managed, with a refilling strategy in place ahead of the peak beverage season, minimizing tariffs' impacts on Q2.

Legacy Business Exit and Intellectual Property Monetization:

  • Exit from Legacy AgTech: Successfully executed a transaction with BioSeries; regained rights to certain soy patents and eliminated $1 million in contingent liabilities from its balance sheet through this. Expect to finalize exiting the legacy AgTech business soon.
  • Remaining Patent: One tomato patent remains under license; potential commercialization efforts are ongoing, but not directly beneficial for Arcadia.

Pending Business Combination:

  • Roosevelt Resources Merger: The anticipated merger with Roosevelt Resources is progressing, with a target completion around mid-August 2025. The revised equity ratio (90-10) aims to provide greater ownership certainty for Arcadia stockholders.

Cash Position and Future Outlook:

  • Cash and Receivables: The company's cash balance at the end of Q1 was $3.2 million, down from $4.2 million at the start of the year. Expected cash inflow from a receivable of approximately $2.5 million scheduled for Q2.
  • Long-term View: The management expresses optimism for continued growth driven by Zola's expansion, upcoming new product launches, and the streamlined focus on core operations post-merger.

Conclusion

Arcadia Biosciences is experiencing strong growth in its Zola brand, successfully reducing operational costs, and actively managing its transition from legacy businesses, all of which position the company favorably for future performance and shareholder value enhancement.

Arcadia Biosciences Earnings History

Earnings Calendar

FAQ

When is the earnings report for RKDA?
Arcadia Biosciences (RKDA) has scheduled its earnings report for Aug 11, 2025 after the markets close.

What is the RKDA price-to-earnings (P/E) ratio?
RKDA P/E ratio as of May 16, 2025 (TTM) is -2.82.

What is the RKDA EPS forecast?
The forecasted EPS (Earnings Per Share) for Arcadia Biosciences (RKDA) for the first fiscal quarter 2025 is $.

What are Arcadia Biosciences's retained earnings?
On its balance sheet, Arcadia Biosciences reported retained earnings of $1.20 million for the latest quarter ending Mar 31, 2025.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT ARCADIA BIOSCIENCES
Arcadia Biosciences
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, Californi...
GOLDEN STAR
Ticker Change Signal Date
IEP
$8.75
11.43% May 09
JLL
$229.63
2.75% May 09
UAA
$5.84
14.90% May 09
IIPR
$54.61
4.30% May 09
MEDP
$300.81
1.61% May 08

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE